



Medicine Protocol for the Administration of Menjugate (Meningococcal Group C conjugate vaccine) by registered nurses and registered midwives to Refugees and Applicants Seeking Protection in Ireland and in the event of an outbreak

This medicine protocol is a specific written instruction for the administration of Menjugate (Meningococcal Group C conjugate vaccine) to Refugees and Applicants Seeking Protection in Ireland (hereafter referred to as vaccine recipients) and in the event of an outbreak by registered nurses and registered midwives. This medicine protocol is valid for the 2024/2025 Health Service Executive (HSE) Primary Childhood Immunisation Programme (PCIP), Schools Immunisation Programme (SIP) and for National Immunisation Advisory Committee (NIAC) recommended catch up immunisation, and in the event of an outbreak as advised by public health.




This medicine protocol enables registered nurses and registered midwives employed in the voluntary and statutory services of the HSE including HSE Community vaccination clinics who have undertaken the required education and training programmes to administer Menjugate (Meningococcal Group C conjugate vaccine) with reference to and guidance from Nursing & Midwifery Board of Ireland (NMBI), National Immunisation Advisory Committee (NIAC), National Immunisation Office (NIO), HSE and in accordance with the Summary of Product Characteristics (SmPC) for Menjugate (Meningococcal Group C conjugate vaccine) as detailed by the Health Products Regulatory Authority (HPRA) at www.hpra.ie

- National Immunisation Advisory Committee (2023) *Anaphylaxis: Immediate Management in the Community* available at: https://rcpi.access.preservica.com/uncategorized/IO_a36f9e4b-4c80-432d-8264-546089359925/
- National Immunisation Advisory Committee *Immunisation Guidelines for Ireland*: Royal College of Physicians of Ireland National Immunisation Advisory Committee available at: <https://www.rcpi.ie/Healthcare-Leadership/NIAC/Immunisation-Guidelines-for-Ireland>
- National Immunisation Office (2024/2025) *Supporting Information for Staff: Schools Immunisation Programme* available at: <https://www.hse.ie/eng/health/immunisation/hcpinfo/schoolproghcp/supportingdoc.pdf>
- National Immunisation Office (2024) Clinical information to support healthcare staff to deliver catch-up vaccination for Refugees and Applicants Seeking Protection in Ireland and in the event of an outbreak available at: <https://www.hse.ie/eng/health/immunisation/hcpinfo/botpipa/clinicalinfobotpipa.pdf>
- National Immunisation Office (2024) *Supporting Information for Vaccinations in General Practice* available at: <https://www.hse.ie/eng/health/immunisation/infomaterials/gpsupportingdocpci.pdf>
- Nursing and Midwifery Board of Ireland (2021) *Code of Professional Conduct and Ethics for Registered Nurses and Registered Midwives*. Dublin: Nursing and Midwifery Board of Ireland available at: <https://www.nmbi.ie/NMBI/media/NMBI/Code-of-Professional-Conduct-and-Ethics.pdf>
- Nursing and Midwifery Board of Ireland (2020) *Guidance for Registered Nurses and Midwives on Medication Administration* available at: <https://www.nmbi.ie/NMBI/media/NMBI/NMBI-Medication-Administration-2020.pdf?ext=.pdf>
- Nursing and Midwifery Board of Ireland (2022) *Practice Standards for Midwives*. Dublin: Nursing and Midwifery Board of Ireland available at: <https://www.nmbi.ie/Standards-Guidance/MidwivesStandards>
- Nursing and Midwifery Board of Ireland (2015) *Recording Clinical Practice. Guidance to Nurses and Midwives*. Dublin: Nursing and Midwifery Board of Ireland available at: <https://www.nmbi.ie/Standards-Guidance/More-Standards-Guidance/Recording-Clinical-Practice>
- Nursing and Midwifery Board of Ireland (2015) *Scope of Nursing and Midwifery Practice Framework*. Dublin: Nursing and Midwifery Board of Ireland available at: <https://www.nmbi.ie/StandardsGuidance/Scope-of-Practice/Nursing-Practise-Scope-Definition>

The Nursing and Midwifery Board of Ireland defines medicine protocols as “written directions that allow for the supply and administration of a named medicinal product by a registered nurse or midwife in identified clinical situations. A medication protocol involves the authorisation of the nurse or midwife to supply and administer a medication to groups of patients in a defined situation meeting specific criteria and who may not be individually identified before presentation for treatment (AnBord Altranais, 2007, page 37).



Medicine Protocol for the Administration of Menjugate (Meningococcal Group C conjugate vaccine) by registered nurses and registered midwives to Refugees and Applicants Seeking Protection in Ireland and in the event of an outbreak

| | |
|---|--|
| Document reference number | Version3-NIO-MenC-December2024 |
| 1.0 Critical elements | |
| Name of Organisation /Setting where medicine protocol applies | Health Service Providers across the voluntary and statutory services of the HSE including HSE community vaccination clinics. This Medicine Protocol applies to: <ul style="list-style-type: none">registered nurses and registered midwives employed in the voluntary and statutory services of the HSE including HSE Community vaccination clinics, congregated settings, temporary clinics and mobile units |
| Date the medicine protocol comes into effect | December 2024 |
| Date for review of medicine protocol | December 2025 |
| Document prepared by | National Immunisation Office (NIO) in collaboration with the Office of the Nursing and Midwifery Services Director (ONMSD) HSE. |
| Names and Signatures of the employing authority who is authorising the implementation of the medicine protocol “On behalf of the authority employing professionals authorised to administer under this medicine protocol, I have read this medicine protocol and authorise its implementation” | Name: Dr. Éamonn O 'Moore Director of National Health Protection Signature:  Name: Dr Colm Henry , Chief Clinical Officer, HSE  Signature: _____ Name: Dr Geraldine Shaw , Nursing and Midwifery Services Director, HSE  Signature: _____ |



| 2.0 Clinical Criteria | | | | | | | | | | | | | | | | | |
|---|--|---|--|----------------|------------|---------------|--------|--------|--------|-----|------------|--------------|--------------------|---------------|--------|---|---|
| Clinical condition for use of the medicine protocol | The clinical condition for which this medicine protocol has been developed is for the active immunisation against and prevention of Meningococcal Group C (Men C) disease. | | | | | | | | | | | | | | | | |
| Circumstances in which the medicine protocol applies | To provide a Menjugate (Meningococcal Group C conjugate vaccine) to Refugees and Applicants Seeking Protection in Ireland (hereafter referred to as vaccine recipients) and in the event of an outbreak as advised by Public Health. | | | | | | | | | | | | | | | | |
| Inclusion criteria for vaccine recipients receiving Menjugate (Meningococcal Group C conjugate vaccine) under this medicine protocol | <p>For primary immunisation</p> <p>For children born on or before the 30th September 2024 the primary schedule consists of 2 doses with the first being administered at 6 months of age and a second dose of Hib/MenC at 13 months of age.</p> <p>For children born on or after the 1st October 2024 the primary schedule consists of 1 dose at 13 months of age</p> <p>For catch up programme</p> <p>Unvaccinated children and adults up to 23 years of age should be vaccinated as per the NIAC catch up schedule as below.</p> <table border="1" data-bbox="448 891 1501 1142"> <thead> <tr> <th>Age</th> <th>4 months to <12 months If born on or before the 30th September 2024</th> <th>1 to < 2 years</th> <th>2-<4 years</th> </tr> </thead> <tbody> <tr> <td>*MenC Vaccine</td> <td>1 dose</td> <td>1 dose</td> <td>1 dose</td> </tr> </tbody> </table> <table border="1" data-bbox="448 1193 1501 1467"> <thead> <tr> <th>Age</th> <th>4 -9 years</th> <th>10 -17 years</th> <th>18 years and older</th> </tr> </thead> <tbody> <tr> <td>*MenC Vaccine</td> <td>1 dose</td> <td>1 dose up to 23 years of age, if Men C containing vaccine not given at age >10years</td> <td>1 dose up to 23 years of age, if Men C containing vaccine not given at age ≥10years</td> </tr> </tbody> </table> <p>For outbreak response: As advised by public health</p> <p>Precaution</p> <ul style="list-style-type: none"> Acute severe febrile illness, defer until recovery <p>Note: The presence of a minor infection such as a mild upper respiratory infection or low grade fever is not a contraindication to immunisation.</p> <p>Note: COVID-19 vaccines (except for COVID-19 vaccine given to children aged 6 months to 4 years where a 14-day interval is recommended) and other vaccines may be administered at the same time or at any interval.</p> | Age | 4 months to <12 months If born on or before the 30 th September 2024 | 1 to < 2 years | 2-<4 years | *MenC Vaccine | 1 dose | 1 dose | 1 dose | Age | 4 -9 years | 10 -17 years | 18 years and older | *MenC Vaccine | 1 dose | 1 dose up to 23 years of age, if Men C containing vaccine not given at age >10years | 1 dose up to 23 years of age, if Men C containing vaccine not given at age ≥10years |
| Age | 4 months to <12 months If born on or before the 30 th September 2024 | 1 to < 2 years | 2-<4 years | | | | | | | | | | | | | | |
| *MenC Vaccine | 1 dose | 1 dose | 1 dose | | | | | | | | | | | | | | |
| Age | 4 -9 years | 10 -17 years | 18 years and older | | | | | | | | | | | | | | |
| *MenC Vaccine | 1 dose | 1 dose up to 23 years of age, if Men C containing vaccine not given at age >10years | 1 dose up to 23 years of age, if Men C containing vaccine not given at age ≥10years | | | | | | | | | | | | | | |
| Exclusion criteria for vaccine recipients receiving Menjugate (Meningococcal Group C conjugate vaccine) under this medicine protocol | Anaphylaxis to any of the vaccine constituents. | | | | | | | | | | | | | | | | |
| Actions to be taken for | All vaccine recipients meeting exclusion criteria must be referred to the clinical lead for | | | | | | | | | | | | | | | | |



Medicine Protocol for the Administration of Menjugate (Meningococcal Group C conjugate vaccine) by registered nurses and registered midwives to Refugees and Applicants Seeking Protection in Ireland and in the event of an outbreak

| <p>those who are excluded from the medicine protocol</p> | <p>an individual assessment.</p> <ul style="list-style-type: none"> • Document action in clinical notes • Where Menjugate (Meningococcal Group C conjugate vaccine) is prescribed following clinical assessment, the nurse or midwife may administer Menjugate (Meningococcal Group C conjugate vaccine) within their scope of practice. <p>Note: In determining their scope of practice, nurses and midwives must make judgements about their competency to carry out a role or activity (NMBI, 2015).</p> | | | | | | | | | | | | |
|--|--|---|------|----------------------|---------------------|-------------------------|---|------------------|---|----------------------|-------------------|----------------|----------------------|
| <p>Description of circumstances and referral arrangements when further advice or consultation is required</p> | <p>Discuss the vaccine recipient with the clinical lead in the event of:</p> <ul style="list-style-type: none"> • Adverse reaction • Other clinical concerns | | | | | | | | | | | | |
| <p>Documentation required to support implementation of the medicine protocol</p> | <p>A consent form must be completed by the parent /legal guardian for all children who receive the Meningococcal Group C Conjugate Vaccine (Menjugate). Children aged 16 years and over consent on their own behalf, once understood and translation of consent is undertaken with support of translator if required. Appropriate details including the batch number must be recorded on the consent form.</p> <p>The following documents will be required at each vaccination session:</p> <ul style="list-style-type: none"> • Vaccination session form • Blank vaccine consent forms • Vaccine Information Leaflets • Patient held record cards/ Vaccine passport • HPRA Adverse Reaction Reporting forms • HSE Incident/Near Miss Report Forms • Post vaccination advice <p>It is the responsibility of each registered nurse or midwife to be familiar with the appropriate documentation to support the safe administration of Menjugate (Meningococcal Group C conjugate vaccine) which includes the following:</p> <ul style="list-style-type: none"> • Medicine Protocol for the administration of Menjugate (Meningococcal Group C conjugate vaccine) by registered nurses and registered midwives to Refugees and Applicants Seeking Protection in Ireland and in the event of an outbreak • NIAC (2023) <i>Anaphylaxis: Immediate Management in the Community</i> available at: https://rcpi.access.preservica.com/uncategorized/IO_a36f9e4b-4c80-432d-8264-546089359925/ | | | | | | | | | | | | |
| <p>3.0 Name of medicine</p> | <p>MENJUGATE 10 micrograms suspension for injection Meningococcal Group C conjugate vaccine</p> <p>Dose: 0.5ml Route: Intramuscular injection</p> <table border="1" data-bbox="448 1581 1501 2051"> <thead> <tr> <th>Patients Age</th> <th>Site</th> <th>Needle length & Size</th> </tr> </thead> <tbody> <tr> <td>Birth to <12 months</td> <td>Vastus lateralis muscle</td> <td>25 mm (Use a 16 mm needle in infants under 2.5 - 3 kg) 23-25 gauge</td> </tr> <tr> <td>12 to <36 months</td> <td>Vastus lateralis or deltoid muscle (depending on muscle mass)</td> <td>25 mm 23-25 gauge</td> </tr> <tr> <td>3 years and older</td> <td>Deltoid muscle</td> <td>25 mm 23-25 gauge</td> </tr> </tbody> </table> | Patients Age | Site | Needle length & Size | Birth to <12 months | Vastus lateralis muscle | 25 mm (Use a 16 mm needle in infants under 2.5 - 3 kg) 23-25 gauge | 12 to <36 months | Vastus lateralis or deltoid muscle (depending on muscle mass) | 25 mm 23-25 gauge | 3 years and older | Deltoid muscle | 25 mm 23-25 gauge |
| Patients Age | Site | Needle length & Size | | | | | | | | | | | |
| Birth to <12 months | Vastus lateralis muscle | 25 mm (Use a 16 mm needle in infants under 2.5 - 3 kg) 23-25 gauge | | | | | | | | | | | |
| 12 to <36 months | Vastus lateralis or deltoid muscle (depending on muscle mass) | 25 mm 23-25 gauge | | | | | | | | | | | |
| 3 years and older | Deltoid muscle | 25 mm 23-25 gauge | | | | | | | | | | | |
| <p>Link to Medicine</p> | <p>Link to Summary of Product Characteristics: https://www.hpra.ie/img/uploaded/swedocuments/Licence_PA0919-004-</p> | | | | | | | | | | | | |



Medicine Protocol for the Administration of Menjugate (Meningococcal Group C conjugate vaccine) by registered nurses and registered midwives to Refugees and Applicants Seeking Protection in Ireland and in the event of an outbreak

| | |
|---|--|
| <p>Details of product information and other data including instructions for supply and administration is available from the HPRA at www.hpra.ie</p> | <p>003_05112021142113.pdf</p> <p>Link to Patient Information Leaflet: https://www.hpra.ie/img/uploaded/swedocuments/pil-2195718-29012018151204-636528355258437500.pdf</p> |
| <p>Procedure for reporting and documentation of errors and near misses involving the medicine</p> | <p>In the case of medicine errors that directly involve the vaccine recipient, i.e. wrong medicine/patient/dose/route being administered or another medicine error, the registered nurse or registered midwife must remain with the vaccine recipient and closely monitor them for any adverse reactions.</p> <p>Vital signs should be recorded and the vaccine recipient should be reviewed by the registered nurse/midwife and/or medical practitioner.</p> <p>The incident must be reported to the relevant line manager as soon as possible. The incident and all actions taken must be promptly recorded in the recipient's notes and the relevant National Incident Management Report Form completed: https://www.hse.ie/eng/about/who/ngpsd/gps-incident-management/nims/nirf-01-v12-person-interactive.pdf</p> <p>For children, the child's parent and/or legal guardian must be informed of the incident.</p> <p>Any suspected adverse reactions associated with medicine errors should be reported to the HPRA as outlined below.</p> <p>Any errors and near misses not involving medications/not directly involving the vaccine recipient (Needle stick injuries etc.), the incident and all actions taken must be promptly recorded on the relevant National Incident Management Report Form and forwarded to the relevant line manager as per local policy. Refer to https://www.hpsc.ie/a-z/emi/algorithms/EMISharpAlgo.pdf</p> |
| <p>Procedure for reporting Adverse Drug Reactions to the HPRA</p> | <p>The relevant nursing or midwifery staff should report to the HPRA any suspected adverse reactions, in accordance with criteria outlined by the HPRA. This reporting may be carried out online at https://www.hpra.ie or through use of the yellow card system which is available in the downloadable format from the HPRA website, or on request from the HPRA.</p> |
| <p>Resources and equipment required for the administration of Menjugate (Meningococcal Group C conjugate vaccine)</p> | <ul style="list-style-type: none">• Menjugate (Meningococcal Group C conjugate vaccine)• Fridge/cool box with minimum/maximum temperature recording device to monitor the cold chain temperature (between +2°C and +8°C)• Disposable kidney dishes/coloured trays• Gauze swabs/Plasters• Sharps bins and bags for disposal of healthcare risk and non-risk waste materials• Alcohol hand sanitiser• Handwashing facilities• Access to telephone• Resuscitation equipment and drugs in accordance with the NIAC (2023) <i>Anaphylaxis: Immediate Management in the Community</i> available at: https://rcpi.access.preservica.com/uncategorized/IO_a36f9e4b-4c80-432d-8264-546089359925/• Safe storage areas for medicines and equipment• Current medicine protocol for Meningococcal Group C Conjugate Vaccine (Menjugate). |
| <p>Audit process to identify</p> | |



| | |
|--|---|
| <p>appropriate use of the medicine protocol or unexpected outcomes</p> | <p>All documentation will be held for review and audit purposes as per local policy.</p> |
| <p>4.0 Information for vaccine recipient /parent/guardian</p> | |
| <p>Advice to be given to the vaccine recipient/parent/legal guardian before treatment</p> <p>Advice to be given to the vaccine recipient/parent/legal guardian after treatment</p> | <p>Reiterate the information provided in the HSE patient information leaflet for the vaccine in the appropriate language and translator support if required.</p> <p>For children, Patient Information Leaflet/Fact Sheet must be supplied with the consent form to each parent/legal guardian prior to administration of the vaccine as above.</p> <p>After Treatment The vaccine recipient must be advised to remain seated in the post vaccination observation area for 15 minutes to allow monitoring of any immediate reaction including possible anaphylactic reaction and must be advised to report any side effects to the registered nurse or registered midwife who is present.</p> |
| <p>Details of any necessary follow-up, action and referral arrangements</p> | <p>In the event of an adverse reaction the registered nurse or midwife must ensure that all procedures are adhered to as outlined in Section 3.</p> |
| <p>5.0 Staff authorised to use this medicine protocol</p> | |
| <p>Professional qualifications, training, experience and competence required prior to working under this medicine protocol</p> | <p>Registered nurse or registered midwife must have completed all of the following:</p> <ol style="list-style-type: none"> 1) Be a Registered Nurse or Registered Midwife, on the active register maintained by the NMBI 2) <i>Primary Childhood Immunisation Programme</i> accessible on www.HSELand.ie 3) Education programme for nurses and midwives on <i>Schools Immunisation Programme</i> and any updates for nurses and midwives accessible on www.HSELand.ie 4) An approved <i>Basic Life Support for Health Care Providers Course</i> within the last two years (i.e. Irish Heart Foundation (IHF)) 5) Initial <i>National Anaphylaxis Education Programme for Health Care Professionals</i> accessible on www.HSELand.ie followed by a two hour classroom based skills workshop. Recertification is required every two years by completing the on-line <i>National Anaphylaxis Education Programme for Health Care Professionals</i> accessible on www.HSELand.ie 6) Children having vaccinations and healthcare procedures: Clinical Holding (Professor Lucy Bray/ONMSD, 2023) available at www.HSELand.ie 7) The registered nurse/midwife must complete the Competency Self-Assessment Form to vaccinate* Refugees and Applicants Seeking Protection in Ireland <p>*Health Service Executive (HSE) Primary Childhood Immunisation Programme (PCIP), Schools Immunisation Programmes (SIP) and the National Immunisation Advisory Committee (NIAC) Catch Up Immunisation Programme available at www.immunisation.ie</p> |

References



Medicine Protocol for the Administration of Menjugate (Meningococcal Group C conjugate vaccine) by registered nurses and registered midwives to Refugees and Applicants Seeking Protection in Ireland and in the event of an outbreak

GlaxoSmithKline Menjugate (Meningococcal Group C conjugate vaccine) *Summary of Product Characteristics and Patient Information Leaflet*, available at www.hpra.ie

Health Products Regulatory Authority available at: www.hpra.ie

National Clinical Guideline No. 30 (2023) – Infection Prevention and Control (IPC)
<https://www.gov.ie/en/publication/a057e-infection-prevention-and-control-ipc/>

National Immunisation Advisory Committee (2023) *Anaphylaxis: Immediate Management in the Community* available at: https://rcpi.access.preservica.com/uncategorized/IO_a36f9e4b-4c80-432d-8264-546089359925/

National Immunisation Advisory Committee *Immunisation Guidelines for Ireland*. Dublin: Royal College of Physicians of Ireland National Immunisation Advisory Committee (*Online Update available at:* <https://www.rcpi.ie/Healthcare-Leadership/NIAC/Immunisation-Guidelines-for-Ireland>

National Immunisation Office (2024) Clinical information to support healthcare staff to deliver catch-up vaccination for Refugees and Applicants Seeking Protection in Ireland and in the event of an outbreak available at: <https://www.hse.ie/eng/health/immunisation/hcpinfo/botpipa/clinicalinfobotpipa.pdf>

National Immunisation Office (2024/2025) *Supporting Information for Staff: Schools Immunisation Programme* available at: <https://www.hse.ie/eng/health/immunisation/pubinfo/schoolprog/suppinfo4staff.pdf>

National Immunisation Office (2024) *Supporting Information for Vaccinations in General Practice* available at: <https://www.hse.ie/eng/health/immunisation/infomaterials/gpsupportingdocpci.pdf>

Nursing and Midwifery Board of Ireland (2021) *Code of Professional Conduct and Ethics for Registered Nurses and Registered Midwives*. Dublin: Nursing and Midwifery Board of Ireland available at: <https://www.nmbi.ie/Standards-Guidance/Code>

Nursing and Midwifery Board of Ireland (2020) *Guidance for Registered Nurses and Registered Midwives on Medication Administration*. Dublin: Nursing and Midwifery Board of Ireland available at: <https://www.nmbi.ie/NMBI/media/NMBI/NMBI-Medication-Administration-2020>

Nursing and Midwifery Board of Ireland (2022) *Practice Standards for Midwives* Dublin: Nursing and Midwifery Board of Ireland available at: <https://www.nmbi.ie/Standards-Guidance/Midwives-Standards>

Nursing and Midwifery Board of Ireland (2015) *Scope of Nursing and Midwifery Practice Framework*. Dublin: Nursing and Midwifery Board of Ireland available at: <https://www.nmbi.ie/Standards-Guidance/Scope-ofPractice/Nursing-Practise-Scope-Definition>

Nursing and Midwifery Board of Ireland (2015) *Recording Clinical Practice. Guidance to Nurses and Midwives*. Dublin: Nursing and Midwifery Board of Ireland available at: <https://www.nmbi.ie/Standards-Guidance/More-Standards-Guidance/Recording-Clinical-Practice>